linjc16/ctgov huggingface dataset:
Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China

Study Overview
=================
Brief Summary
-----------------
Critically ill Patients are at high risk to develop deep venous thrombosis. However, despite receiving of a standard dose of Low-molecular-weight Heparin（LMWH）, many patients still develop life-threatening embolism. The purpose of this study is to evaluate the anti-Xa levels of different dosing regimens of LMWH in critically ill patients in China.

Official Title
-----------------
Evaluation of Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China

Conditions
-----------------
Anti-Xa, Critically Ill

Intervention / Treatment
-----------------
* Diagnostic Test: anti Xa level


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult Critically ill patients Exclusion Criteria: Contraindication to use of LMWH. Intracranial bleeding/stroke, hematoma or bleeding disorder. Use Heparin anticoagulant therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| LMWH qd<br>receiving Low-molecular-weight Heparin（LMWH）qd | Diagnostic Test: anti Xa level<br>* monitoring the anti-Xa level according to LMWH emploing<br>|
| LMWH q12h<br>receiving Low-molecular-weight Heparin（LMWH）q12h | Diagnostic Test: anti Xa level<br>* monitoring the anti-Xa level according to LMWH emploing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anti-Xa Levels |  | six months |
Metabolite Biomarkers Related to Acute Rejection in Kidney Transplantation

Study Overview
=================
Brief Summary
-----------------
The development of acute rejection can only be considered in cases with increasing serum creatinine in patients with kidney transplantation. However, the serum creatinine itself is not specific but also accurate for detection of acute rejection. So The specific biomarker is required for acute rejection of kidney transplant. In this study, the investigators will enroll 200 consecutive kidney transplant patients in Seoul National University Hospital and follow up. Serial collection of urine and serum will be done. Acute rejection specific urine metabolite will be found by LC MS/MS.

Official Title
-----------------
Identification of Metabolite Biomarkers Related to Acute Rejection of Patients With Kidney Transplantation

Conditions
-----------------
Kidney Transplantation, Rejection Acute Renal

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Kidney transplant patients in Seoul National University Hospital Patients with triple maintenance immunosuppression including Tacrolimus, mycophenolate and steroid Exclusion Criteria: History of other organ transplantation ABOi and/or crossmatch(+) transplantation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| biomarker for acute rejection in kidney transplantation | urine metabolite which is specific for kidney transplant rejection | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
metabolomics, biomarker, acute rejection
Safety, Efficacy, and Tolerance of Pico-Salax for Colon Cleansing Prior to Colonoscopy in an Elderly Population

Study Overview
=================
Brief Summary
-----------------
This study aims to further define the appropriate population for Pico-Salax, a purgative used prior to colonoscopy. Patients over the age of 70 years with normal renal function scheduled for colonoscopy will receive Pico-Salax and have pre and post preparation bloodwork and electrocardiograms (ECGs).

Official Title
-----------------
Safety, Efficacy, and Tolerance of Pico-Salax for Colon Cleansing Prior to Colonoscopy in an Elderly Population

Conditions
-----------------
Colon Cleansing

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >70 years Exclusion Criteria: renal dysfunction congestive heart failure ileus

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| elderly patients<br>patients older than 70 years with normal renal function | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum electrolyte changes pre and post preparation |  | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colonoscopy, preparation, safety, elderly
Effect of Hyoscine and Promethazine on Labor Pain

Study Overview
=================
Brief Summary
-----------------
It is always considered to shorten the duration of delivery without compromising the mother and fetus by obstetrics. Hyoscine and Promethazine are used widely in hospital and research is very limited, with conflicting results regarding the efficacy of these two drugs. So the investigators decided to compare of effect of hyoscine N-butyl bromide and Promethazine on length of active phase of the first stage of labor.

Official Title
-----------------
Principal Investigator

Conditions
-----------------
Labor Pain

Intervention / Treatment
-----------------
* Drug: Hyoscine
* Drug: Promethazine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-35 yrs, primiparous, having single fetus with cephalic presentation, gestational age 37-42 weeks, having no medical diseases, having no history of hospitalization due to psychological diseases, having no addiction to cigarette, having no complications during pregnancy such as hypertension, BMI< 26 Exclusion Criteria: bleeding CPD use of PG or Oxytocin fetus distress

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Promethazine<br>25 mg of promethazine | Drug: Promethazine<br>* The samples were randomly allocated to inject of 25 mg of promethazine IM in dilatation 3-5cm.<br>|
| Experimental: Hyoscine<br>20 mg of hyoscine | Drug: Hyoscine<br>* The samples were randomly allocated to inject of 20 mg of hyoscineIM in dilatation 3-5cm.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of Hyoscine and Promethazine on labor pain |  | up to 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hyoscine,, Promethazine,, The first stage of labor,, Labor pain
Evaluation of the New Acceleromyograph TOF 3D

Study Overview
=================
Brief Summary
-----------------
The TOF 3D is a new acceleromyograph designed to assess the degree of a neuromuscular block during anesthesia. The study compares the new three-dimensional technique with the established TOF Watch SX.

Detailed Description
-----------------
The TOF 3D is a new acceleromyograph designed to assess the degree of a neuromuscular block during anesthesia. The study compares the new three-dimensional technique with the established TOF Watch SX. The time course of a neuromuscular block (onset, maximal block, time to recovery) is assessed simultaneously with both devices in 50 patients undergoing elective gynecologic surgery requiring neuromuscular block. The validity and reliability of the new technique is evaluated with a Bland-Altman- analysis.

Official Title
-----------------
Evaluation of the New Three-dimensional Acceleromyograph TOF 3D Compared With the Established TOF Watch SX.

Conditions
-----------------
Assessment of a New Acceleromyograph, Neuromuscular Block

Intervention / Treatment
-----------------
* Diagnostic Test: acceleromyography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing elective gynecologic surgery requiring general anesthesia and neuromuscular block Exclusion Criteria: anticipated difficult airway Risk of pulmonary aspiration acute infection pregnancy renal or hepatic insufficiency neuromuscular disease chronic intake of drugs influencing neuromuscular block

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: adductor pollicis AP<br>Measurement site: M.adductor pollicis of both arms. | Diagnostic Test: acceleromyography<br>* Simultaneous measurement of the time course of a neuromuscular block with 2 acceleromyographs<br>|
| Experimental: Corrugator supercilii CS<br>Measurement site: M. corrugator supercilii at both sides | Diagnostic Test: acceleromyography<br>* Simultaneous measurement of the time course of a neuromuscular block with 2 acceleromyographs<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TOF-R 90% | Difference of the 90% train-of-four (TOF) recovery time between both devices | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| repeatability (precision) | Variance of 10 consecutive measurements around a linear regression line for each device | 12 months | 
| bias and limits of agreement (Bland-Altman analysis) | Difference between both devices against the average of both measurements (bias +- 2SD) | 12 months |
Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine if delta-haemolysin production deficiency of Staphylococcus aureus is a marker in favour of chronic infections on implants

Official Title
-----------------
Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR

Conditions
-----------------
Bone and Joint Infection, Staphylococcus Aureus

Intervention / Treatment
-----------------
* Other: Delta-haemolysin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients having implant infection due to S. aureus treated by DAIR Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Deficiency of delta-hemolysine<br>Implant infected by Staphylococcus aureus with delta-haemolysin Production Deficiency | Other: Delta-haemolysin<br>* comparison of groups having infection with S. aureus with and without delta-haemolysin Production<br>|
| Presence of delta-hemolysine<br>Implant infected by Staphylococcus aureus with delta-haemolysin Production | Other: Delta-haemolysin<br>* comparison of groups having infection with S. aureus with and without delta-haemolysin Production<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of infection with or witout delta-haemolysin in Staphylococcus Aureus | patients, profile of the bacterium, medical and chirurgical treatment, rate. comparison between the 2 groups | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of Treatment Failure | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin. Analyse of risk factor. Comparison between the 2 groups | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bone and Joint Infection, Staphylococcus Aureus, chronic infection
Contactless Detection of Sleep Apnea

Study Overview
=================
Brief Summary
-----------------
In this study the inestigators aim to validate the performance of Sleepiz One+ for sleep apnea detection during routine diagnostic sleep studies. Patients who are prescribed polysomnography study will be asked to participate and undergo a simultaneous sleep recording with radar sensor-based device.

Official Title
-----------------
Validation of a Contactless Sensor for Sleep Apnea Diagnosis Against Polysomnography

Conditions
-----------------
Sleep Apnea

Intervention / Treatment
-----------------
* Device: Sleepiz One+ vs. polysomnography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18years Ability and consent to undergo electrophysiological routine assessment Patients suspected to suffer from sleep apnea or any other sleep related disorder Exclusion Criteria: Previous enrollment into the current study, Enrollment of the investigator, his/her family members and other dependent persons Cardiac pacemaker or another implanted electrical device Women who are pregnant or breastfeeding Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, delirium etc. of the participant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients suspected of suffering from sleep apnea<br> | Device: Sleepiz One+ vs. polysomnography<br>* Simultaneous sleep recording with polysomnography and Sleepiz One+ device<br>|
| Experimental: Healthy volunteers<br> | Device: Sleepiz One+ vs. polysomnography<br>* Simultaneous sleep recording with polysomnography and Sleepiz One+ device<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Binary classification of subjects based on their sleep apnea severity (AHI ≥= 15) made by Sleepiz One+, compared to PSG data manually scored by sleep technicians |  | 1 Night |
The Role of Genetic Factors in the Development of Arterial Hypertension in the Kazakh Population

Study Overview
=================
Brief Summary
-----------------
This is a GWAS study that aims to identify possible candidate genes associate to arterial hypertension by exploring single nucleotide polymorphism (SNP) in a group of arterial hypertension, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with arterial hypertension

Detailed Description
-----------------
A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Official Title
-----------------
Preventive and Personalized Medicine (2021-2023)

Conditions
-----------------
Arterial Hypertension

Intervention / Treatment
-----------------
* Genetic: DNA analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Persons with confirmed arterial hypertension; The age of patients is from 18 to 55 years old inclusive; Persons of Kazakh nationality, whose paternal and maternal grandparents identify themselves as Kazakhs; Persons who are able and willing to provide written informed consent; Persons capable and willing to comply with the research protocol; Exclusion Criteria: Persons under 18 and over 55; Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent; Pregnant or lactating women; Tuberculosis of any localization in the active phase and in history; Severe and decompensated diseases of the liver and kidneys, cardiovascular system; Severe and decompensated course of endocrine diseases; Autoimmune diseases; Systemic diseases; Cancer.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental group:<br>Patients with arterial hypertension | Genetic: DNA analysis<br>* GWAS<br>|
| Control group<br>Patients without arterial hypertension | Genetic: DNA analysis<br>* GWAS<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of SNPs associated with arterial hypertension | Using GWAS to identify candidate genes associate with arterial hypertension | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GWAS
Online Surveys to Assess the Perception and Performance of Imaging and Associated Aspects

Study Overview
=================
Brief Summary
-----------------
In this exploratory study, the researchers would like to investigate the background, perception, current use practices, potential unmet needs and/or challenges in regard to imaging procedures, imaging technology, or any other aspect related to the broader field of imaging.

Detailed Description
-----------------
The researchers plan to include volunteer participants to complete these surveys. The goal of these exploratory efforts will be to increase the currently very limited information available in the topics of interest stated above, and the findings, even if only from limited group of respondents, will help guide research development, prepare for design of clinical trials, guide special interest groups, and serve as role data for appropriate scientific publications.

Official Title
-----------------
Online Surveys to Assess the Perception and Performance of Imaging Associated Aspects

Conditions
-----------------
Perception of Imaging

Intervention / Treatment
-----------------
* Other: Online surveys


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female participants who have access to the online survey tool and can read and write in English Exclusion Criteria: None, as this is voluntary

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Volunteer participants<br>Volunteer participants will participate in surveys assessing their perception of various imaging aspects. | Other: Online surveys<br>* The investigators are recruiting health care providers for these surveys that are involved in or use imaging.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perception of PET/CT imaging agent Y-90 | To evaluate participants' perceptions of Y-90 using a likert scale on an online survey | through study completion, on average 2-5 years | 
| Perception of PET/CT imaging agent NaF | To evaluate participants' perceptions of NaF using a likert scale on an online survey | through study completion, on average 2-5 years | 
| Perception of MRI contrast agents | To evaluate participants' perceptions of MR contrast agents using a likert scale | through study completion, on average 2-5 years |